Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Diamondback Energy Inc (FANG) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Diamondback Energy IncTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Diamondback Energy Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Diamondback Energy Inc trades at $200.85 (market cap $56.48B), while Regeneron Pharmaceuticals Inc trades at $796.95 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and Diamondback Energy Inc pays the higher dividend (2.18%). Which is the better fit depends on your goals.

FANGREGN
Market Cap
$56.48B$82.06B
Sector
EnergyHealth
52-Week High
$213.69$812.27
52-Week Low
$134.53$555.51
Enterprise Value
$68.63B$76.77B
Dividend Yield
2.18%0.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Diamondback Energy Inc

Diamondback Energy (FANG) trades at $200.97, up 1.01% today, with bullish technical signals and strong earnings beats in Q1 and Q2 2026. The stock benefits from high oil prices, production growth, and a 90% analyst buy rating. Recent news highlights Q2 earnings surpassing estimates, driven by operational efficiency and raised 2026 output guidance. Cash flow from operations improved to $8.76 billion in 2025, though net income margin declined to 8.64%.

The outlook is positive, with a consensus price target of $236.63 offering ~18% upside, supported by debt reduction and Permian Basin strength. Risks include oil price volatility, margin pressure from rising costs, and geopolitical supply disruptions affecting global markets. Institutional inflows, like Balefire LLC's recent purchase, reinforce confidence in growth prospects.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $797.99, down 1.24% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong fundamentals with a 27.86% net income margin and consistent earnings beats, though revenue growth is modest. Recent news highlights a class action lawsuit related to clinical trial disclosures, creating near-term sentiment headwinds despite positive analyst coverage.

Outlook remains supported by robust profitability and a bullish analyst consensus, but risks include legal overhangs and potential volatility from trial outcomes. The stock's valuation at a P/E of 19.72 appears reasonable given earnings strength, though investors should weigh litigation risks against fundamental resilience.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Diamondback Energy Inc

Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.

Read more on FANG

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN